PROF OF CLIN-HCOMP
M_NeuSrg-Central Admin
+1 415 353-7500
We studied whether synthetic CBD (from Insys) could control brain tumors in a mouse model; results were unclear and Insys was not able to provide further support for more studies. At present, we also are studying how our patient population uses CBD and THC and why and whether it may impact survival. This project is entitled Impact of Cannabis and Synthetic Cannabinoid Use on Quality of Life in Patients with Central Nervous System Tumors (ICANCNS-QOL)
Publications
IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastoma.
bioRxiv : the preprint server for biology
Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Cancer discovery
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival.
Neuro-oncology advances
A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma.
Journal of neuro-oncology
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.
JAMA oncology
NRG-BN002: Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed GBM.
Neuro-oncology
Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma.
Scientific reports
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
Acta neuropathologica
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.
Nature medicine
Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways.
Cancer discovery
Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect.
Neuro-oncology advances
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma.
Frontiers in oncology
Targeting the IL4 Receptor with MDNA55 in Patients with Recurrent Glioblastoma: Results of a Phase 2b Trial.
Neuro-oncology
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.
Research square
Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Recent advances in the molecular prognostication of meningiomas.
Frontiers in oncology
NCCN Guidelines� Insights: Central Nervous System Cancers, Version 2.2022.
Journal of the National Comprehensive Cancer Network : JNCCN
Therapeutic and Supportive Effects of Cannabinoids in Patients with Brain Tumors (CBD Oil and Cannabis).
Current treatment options in oncology
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.
Acta neuropathologica
CDK 4/6 inhibitors for the treatment of meningioma.
Frontiers in oncology
Intratumor and informatic heterogeneity influence meningioma molecular classification.
Acta neuropathologica
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Clinical cancer research : an official journal of the American Association for Cancer Research
Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities.
Nature genetics
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance).
Neuro-oncology advances
Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143.
Neuro-oncology advances
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T-cell response in low-grade gliomas.
The Journal of clinical investigation
Mouse models of glioblastoma for the evaluation of novel therapeutic strategies.
Neuro-oncology advances
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.
Neuro-oncology advances
A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma.
Journal of neuro-oncology
Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay.
Neuro-oncology advances
Modified RANO (mRANO), iRANO, and standard RANO response to convection-enhanced delivery of IL4R-targeted immunotoxin MDNA55 in recurrent glioblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research
The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment.
Neuro-oncology advances
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN
Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults.
Neuro-oncology advances
The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paraganglioma.
Acta neuropathologica
Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor.
Acta neuropathologica communications
The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment.
Journal of neuro-oncology
A systematic review and meta-analysis examining the effects of cannabis and its derivatives in adults with malignant CNS tumors.
Neuro-oncology practice
Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas.
Acta neuropathologica
Editorial. Chronic convection-enhanced delivery: the next frontier in regional drug infusion for glioblastoma.
Journal of neurosurgery
Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival.
Neuro-oncology practice
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Nature medicine
Risk factors of radiotherapy-induced cerebral microbleeds and serial analysis of their size compared with white matter changes: A 7T MRI study in 113 adult patients with brain tumors.
Journal of magnetic resonance imaging : JMRI
Advances in multidisciplinary therapy for meningiomas.
Neuro-oncology
Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60.
Journal of neuro-oncology
Attitudes toward fertility and fertility preservation in women with glioma.
Neuro-oncology practice
Using genomics to guide treatment for glioblastoma.
Pharmacogenomics
The genetic landscape of gliomas arising after therapeutic radiation.
Acta neuropathologica
Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma.
Journal of neuro-oncology
Primary brain tumours in adults.
Lancet (London, England)
Novel and Prospective Molecular Targets for Therapy of Intracranial Gliomas.
Progress in neurological surgery
A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle.
Nature communications
MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
AJR. American journal of roentgenology
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.
The Lancet. Oncology
NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.
Journal of the National Comprehensive Cancer Network : JNCCN
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
Cancer chemotherapy and pharmacology
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research
Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history.
Clinical neuropathology
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
The Lancet. Oncology
Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes.
Journal of neuro-oncology
The Effect of Molecular Diagnostics on the Treatment of Glioma.
Current oncology reports
Chordoid glioma of the third ventricle: report of a rapidly progressive case.
Journal of neuro-oncology
A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
Cancer chemotherapy and pharmacology
Clinical trial endpoints for patients with gliomas.
Neuro-oncology practice
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Neuro-oncology
Treatment options for recurrent high-grade gliomas.
CNS oncology
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
Journal of neuro-oncology
Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.
Journal of neuro-oncology
Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
Journal of neuro-oncology
The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma.
Academic radiology
Interventional MRI-guided catheter placement and real time drug delivery to the central nervous system.
Expert review of neurotherapeutics
Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience.
Journal of neuro-oncology
Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials.
Translational oncology
Central Nervous System Cancers, Version 1.2015.
Journal of the National Comprehensive Cancer Network : JNCCN
The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.
Neurosurgery
Epidemiology and diagnosis of brain tumors.
Continuum (Minneapolis, Minn.)
Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Molecular cancer therapeutics
Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
Seminars in oncology
Familial gliomas: cases in two pairs of brothers.
Journal of neuro-oncology
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Neuro-oncology
Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.
Seminars in oncology
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
Neuro-oncology
A roundtable discussion on the clinical challenges and options for the treatment of glioblastoma: introducing a novel modality, TTFields.
Seminars in oncology
Central nervous system cancers.
Journal of the National Comprehensive Cancer Network : JNCCN
Disseminated progression of glioblastoma after treatment with bevacizumab.
Clinical neurology and neurosurgery
Endpoints for clinical trials and revised assessment in neuro-oncology.
Current opinion in neurology
Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein.
Clinical cancer research : an official journal of the American Association for Cancer Research
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment.
Neurosurgery
General and neurological complications of targeted therapy.
Handbook of clinical neurology
Conditional probability of survival in patients with newly diagnosed glioblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Anti-angiogenic therapy in glioma.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Central nervous system cancers.
Journal of the National Comprehensive Cancer Network : JNCCN
Identifying the needs of brain tumor patients and their caregivers.
Journal of neuro-oncology
Medical management of brain metastases.
Neurosurgery clinics of North America
Impact of bevacizumab chemotherapy on craniotomy wound healing.
Journal of neurosurgery
Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.
Neuro-oncology
Recent advances in therapy for glioblastoma.
Archives of neurology
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
Neuro-oncology
Immunostimulants for malignant gliomas.
Neurosurgery clinics of North America
Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma.
Journal of neuro-oncology
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Preoperative prognostic classification system for hemispheric low-grade gliomas in adults.
Journal of neurosurgery
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
Journal of neuro-oncology
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).
Journal of neuro-oncology
Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy.
International journal of radiation oncology, biology, physics
Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme.
Journal of neuro-oncology
Therapeutic advances for glioblastoma multiforme: current status and future prospects.
Current oncology reports
Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme.
Neurosurgical focus
Diagnosis and treatment of recurrent high-grade astrocytoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Glial tumors: the current state of scientific knowledge.
Clinical neurosurgery
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Neuro-oncology
GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials.
Neuro-oncology
A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma.
International journal of radiation oncology, biology, physics
Small molecule and monoclonal antibody therapies in neurooncology.
Cancer control : journal of the Moffitt Cancer Center